Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03706-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Jiaojiao Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 20120…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Lymphocytes, Tumor-Infiltrating, Benzofurans, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai.
Abstract (Originalsprache)
Tumor-infiltrating lymphocyte (TIL) deficiency is the most conspicuous obstacle to limit the cancer immunotherapy. Immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibody, have achieved great success in clinical practice. However, due to the limitation of response rates of ICIs, some patients fail to benefit from monotherapy. Thus, novel combination therapy that could improve the response rates emerges as new strategies for cancer treatment. Here, we reported that the natural product rocaglamide (RocA) increased tumor-infiltrating T cells and promoted Th17 differentiation of CD4 + TILs. Despite RocA monotherapy upregulated PD-1 expression of TILs, which was considered as the consequence of T cell activation, combining RocA with anti-PD-1 antibody significantly downregulated the expression of PD-1 and promoted proliferation of TILs. Taken together, these findings demonstrated that RocA could fuel the T cell anti-tumor immunity and revealed the remarkable potential of RocA as a therapeutic candidate when combining with the ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
- Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. zhushiguo@shutcm.edu.cn.
- Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. yaochao@shutcm.edu.cn.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
Zitieren
APA
Luo, J., Ng, W., Liu, Y., Wang, L., Gong, C., Zhou, Y., Fang, C., Zhu, S., & Yao, C. (2024). Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03706-5
Vancouver
Luo J, Ng W, Liu Y, Wang L, Gong C, Zhou Y, et al. Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03706-5
BibTeX
@article{Luo2024,
author = {Luo, Jiaojiao and Ng, Wanyi and Liu, Yangli and Wang, Lixin and Gong, Chenyuan and Zhou, Yufu and Fang, Cheng and Zhu, Shiguo and Yao, Chao},
title = {Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03706-5}
}
EUVIMED